Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News DURECT Corp DRRX

Healthcare
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:DRRX)

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

PR Newswire 9 days ago

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

PR Newswire November 6, 2024

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

PR Newswire October 17, 2024

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

PR Newswire September 25, 2024

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

PR Newswire September 4, 2024

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

PR Newswire August 13, 2024

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update

PR Newswire August 7, 2024

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

PR Newswire May 21, 2024

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

PR Newswire May 13, 2024
View More News ››

Opinion & Analysis (NDAQ:DRRX)

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'

Streetwise Reports July 24, 2019

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

Streetwise Reports March 14, 2019

DURECT Receives Return on Schizophrenia Drug Approval

Streetwise Reports October 4, 2018

Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug

Streetwise Reports August 2, 2018

Progress in pain control and liver disease programs spurs rise in company's rating

The Life Sciences Report July 19, 2017

Analysts take note as small-cap biotech completes early enrollment for Phase 3 trial

The Life Sciences Report July 6, 2017
View More Opinion ››

Bullboard Posts (NDAQ:DRRX)

DURECT Corporation to Present Data on Larsucosterol at The L

NEWS: $DRRX DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024DURECT Corporation to Present Data on...
whytestocks - October 17, 2024

DURECT Corporation Announces Phase 3 Registrational Trial De

BREAKING NEWS: $DRRX DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated...
whytestocks - September 25, 2024

Flava of the day

Go durect
Nibinator - November 8, 2023

watching this one for

an entry position,is looking good at these prices,I have been away for most of the summer having a good time,but it is time to get back...
coolfooldumbguy - August 23, 2019

Intermediate target $1.46 - $1.52

Technical Events 5 bullish - closest target $1.46 - $1.52
tbaggin - March 17, 2016

Insider buying

Felix Theeuwes – who is at present the Chairman and CSO — purchased some 70,000 shares of Durect Corp, with market value of...
tbaggin - March 16, 2016
View more Bullboard ››

Copper Lake Resources Ltd.

Copper Lake Resources Ltd.

Copper Lake Resources Ltd. is a Canadian mineral exploration and development company with interests in two projects both ...
View More »